“Some of the early data that came out of the [ECHO] trial that led to this approval does suggest that it may be beneficial in some high-risk patients,” Tycel Phillips, MD, said.
Approval Alert | Acalabrutinib Plus Bendamustine/Rituximab in Previously Untreated MCL
The FDA has approved acalabrutinib in previously untreated MCL based on results from the phase 3 ECHO trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
More Global Expertise and Talent Are Needed to Administer Cell Therapies
2
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
3
Raludotatug Deruxtecan Shows Promise in Platinum-Resistant Ovarian Cancer
4
Examining the Full Scope of Future Advancements in Radiation Oncology
5
